Description: Quality of life (QoL) can be an aspect of cancer treatment that is often missed as there are no medical instrument to accurately measure such the QoL of treatment. In this symposium, we want to explore evidence behind Patient Reported Outcomes (PROs) and how it might affect the patient experience, in a prostate cancer perspective.
Chairs: A/Prof Arun Azard, Peter Maccallum Cancer Centre, Melbourne
A/Prof Alicia Morgan, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
Daniel Khalaf, BC Cancer Agency, Vancouver
This morning symposium is sponsored by Janssen.
Description: Melanoma is currently the 3rd most common cancer in both men and women in Australia. With this trend, it is important that the landscape of treatment options evolve to combat this. In this session, we will explore the melanoma patient trends of today and where they might head. We will also look at the data of current available therapies in BRAF-mutant metastatic melanoma, with a focus on newcomer BRAFTOVI® + MEKTOVI®, a BRAF/MEK inhibitor combination that was PBS listed in April 2020.
Chairs: Prof Mark Smithers, Surgeon, Director, Upper GI and Soft Tissue Unit, Chairman Queensland Melanoma Project, Princess Alexandra Hospital
Prof David Whiteman, Medical Epidemiologist, QIMR Berghofer
A/Prof Victoria Atkinson, Medical Oncologist, Princess Alexandra Hospital, Greenslopes Private Hospital
Dr Fiona Paxton-Hall, Medical Oncology Advanced Trainee, Princess Alexandra Hospital
This morning symposium is sponsored by Pierre Fabre Australia.
10:05 AM Panel Discussion
12:35 PM Panel Discussion
12:35 PM Panel discussion
12:30 PM Panel Discussion with additional panel members: Cassandra Dickens & Amelia Lewis